Agios Pharma (NASDAQ:AGIO) Receives a Downgrade
In a note distributed to Clients today, Leerink Partners cut shares of Agios Pharma (NASDAQ:AGIO) to a Mkt Perform rating from the previous Outperform rating.
From a total of 5 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO) stock, 3 rate it a ”Buy”, 0 a “Sell”, and 5 a ”Hold”. This means that 38% of the ratings are positive. The highest target price is $130 while the lowest target price is $70. The mean of all analyst targets is $94.4 with a 77.10% above today’s ($51.61) stock price. Agios Pharmaceuticals was the topic of 7 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Roth Capital maintained shares on November 9 with “Neutral” rating. Northland Capital initiated AGIO stock in a recent report from July 23 with “Outperform” rating.
Approximately 658,596 shares of stock traded hands or 7.95% up from the average. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has declined 35.62% since May 4, 2015 and is downtrending. It has underperformed by 34.54% the S&P500.
The overall sentiment of institutions has decreased to 1.11 in Q2 2015. Its down 0.17, from 1.28 in 2015Q2. The ratio is negative, as 31 institutions have sold all the shares of Agios Pharmaceuticals Inc that they owned while 44 funds have taken shares off the table. 25 funds have purchased shares for the first time while 58 added to their positions. These institutions now hold 40.44 million shares or 35.61% more than the 29.82 million shares they owned in 2015Q2.
The Fund Flagship Ventures 2007 General Partner Llc currently is holding shares equating to 85.66% of its total portfolio in Agios Pharmaceuticals Inc representing a total of 1.93 million shares. Another fund,Bb Biotech Ag, is holding a total of 2.11 million shares equating to 4.72% of their holdings. Additionally, Parametrica Management Ltd has a 4,866 share stake in Agios Pharmaceuticals Inc which represents 2.16% of their total portfolio. The Fund, Opus Point Partners Management Llc, based out of New York, has also built up a stake in the stock, which represents a total of 1.79% of their total portfolio. Finally Eventide Asset Management Llc, a fund which is based in the state of Massachusetts reported a total holdings of 244,900 shares.
Insider activity is a very important aspect to track on any stock. Going back to March 9, 2015, shareholders of Agios Pharmaceuticals Inc have witnessed 0 insider buys, and a total of 17 sales equating to a net activity of approximately $18.02 million . Cantley Lewis Clayton Jr. sold 9,704 shares worth approximately $593,497. Higgons John Duncan sold 20,000 shares worth approximately $1.42 million. Biller Scott sold 5,500 shares worth approximately $387,420. Goddard Glenn sold 6,000 shares worth approximately $515,820. The company insider Bowden Christopher sold 5,000 shares worth $603,350.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $2.27 billion. The Firm is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It currently has negative earnings. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells.
According to Zacks Investment Research, “Agios Pharmaceuticals, Inc. is a biopharmaceutical company. It discovers and develops therapeutics in the field of cancer metabolism and inborn errors of metabolism. The Company’s products include AG-221, AG-120, enzyme glutaminase and AG-348. Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.” Get a free copy of the Zacks research report on Agios Pharmaceuticals Inc (AGIO).